Our Profile

Dr. Reddy’s – South Africa operation is a wholly-owned subsidiary and one of the leading generics players in the country. With a dedicated field force we focus on key therapeutic areas like Central Nervous System (CNS) and Primary Care.

Our business performance in South Africa has been phenomenal in the last few years. The overall revenue as per FY10 has been at $9.4 million enlisting a 56% growth. Our top-five products including Omez, Cifloc, Citraz, Amlate and DRL-Moxifloxacin contribute to over 50% of revenue.

Our advantageous position is ensured through the presence of key contributors in our business model. Our Research & Development capability helps us ensure enhanced FTL Opportunities through non-infringing pdts and supports differentiation with products and competitors. Alongside, our in-house API manufacturing capabilities assures cost competitiveness in both private and tender based markets. Our Formulation capabilities and strong business development team ensures high-quality in-house product pipeline, shapes licensing strategy to maximize market share and enrich the product basket. All the more our committed filed force has also been promising in recent years while reaching to all segments of the market.

In the South Africa Generic market we are ranked 18th in terms of Value and 20th in terms of volume (Source: IMS-SA IGMS, MAT, Nov. 2010).